Page last updated: 2024-09-03

gefitinib and dinoprostone

gefitinib has been researched along with dinoprostone in 9 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(dinoprostone)
Trials
(dinoprostone)
Recent Studies (post-2010) (dinoprostone)
5,2315662,91929,1051,3466,357

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)dinoprostone (IC50)
Prostaglandin E2 receptor EP1 subtypeHomo sapiens (human)0.0155
Prostaglandin E2 receptor EP4 subtypeHomo sapiens (human)0.0031
Prostaglandin E2 receptor EP4 subtypeRattus norvegicus (Norway rat)0.0021
Prostaglandin E2 receptor EP3 subtypeHomo sapiens (human)0.002
Prostaglandin E2 receptor EP2 subtypeHomo sapiens (human)0.0087
Prostacyclin receptorHomo sapiens (human)0.26
Prostaglandin E2 receptor EP2 subtypeRattus norvegicus (Norway rat)0.0052

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's4 (44.44)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Altundag, K; Altundag, O; Boruban, C; Silay, YS1
Aasrum, M; Christoffersen, T; Dajani, OF; Guren, TK; Lilleby, P; Meisdalen, K; Sandnes, D; Thoresen, GH; Tveteraas, IH1
Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A1
Kim, YM; Park, SY; Pyo, H1
Hudish, TM; Karoor, V; Keith, RL; Le, M; Miller, YE; Mozer, AB1
Aasrum, M; Christoffersen, T; Dajani, O; Guren, T; Müller, KM; Sandnes, D; Tveteraas, IH; Ødegård, J1
Ciccone, V; Costanza, F; Donnini, S; Morbidelli, L; Terzuoli, E; Ziche, M1
Beloueche-Babari, M; Delgado-Goñi, T; Galobart, TC; Leach, MO; Normantaite, D; Wantuch, S; Whittaker, SR1

Other Studies

9 other study(ies) available for gefitinib and dinoprostone

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome

2005
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
    Journal of cellular physiology, 2008, Volume: 214, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cells, Cultured; Culture Media, Serum-Free; Cyclin D; Cyclins; Dinoprostone; DNA; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation; Hepatocytes; Liver Neoplasms; Male; Pertussis Toxin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins

2008
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Cancer, 2009, May-15, Volume: 115, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines

2009
Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:8

    Topics: Cyclooxygenase 2; Dinoprostone; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Protein Biosynthesis; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Transcription, Genetic

2009
Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:1

    Topics: Adenoma; Animals; Antineoplastic Agents; Cadherins; Cytochrome P-450 Enzyme System; Dinoprostone; Epoprostenol; ErbB Receptors; Female; Gefitinib; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction

2010
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
    Journal of experimental & clinical cancer research : CR, 2012, Sep-11, Volume: 31

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dinoprostone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction

2012
mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
    Prostaglandins & other lipid mediators, 2019, Volume: 143

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cisplatin; Dinoprostone; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Molecular Targeted Therapy; Prostaglandin-E Synthases; Signal Transduction

2019
Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
    British journal of cancer, 2020, Volume: 122, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dinoprostone; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mitochondria; Mutation; Prostaglandin-E Synthases; Proto-Oncogene Proteins B-raf; Pyruvate Carboxylase; Signal Transduction; Skin Neoplasms; Vemurafenib

2020
chemdatabank.com